Skip to main content
. 2021 May 21;13(11):2521. doi: 10.3390/cancers13112521

Figure 3.

Figure 3

The performance of AUROC combining both CD45neg EpCAMpos CTCs (based on the continuous cell count model) CD45neg EpCAMneg cell counts (based on the cutoff point of ≥400 cells) for the prediction of the presence or absence of CRC (71 free of CRC subjects vs. 73 CRC patients). The AUROC was evaluated to be 0.893 (95%CI: 0.842, 0.944).